Surgery Partners, Inc. (SGRY) Presents at Barclays 28th Annual Global Healthcare Conference Prepared Remarks Transcript

CEO J. Evans said Surgery Partners is facing a payer-mix/headwind after Medicare Advantage dynamics and independent physician/primary-care relationships reduced capacity for commercial patients, noting the company did not react quickly enough. He expects recovery over time and highlighted an anomalous market where high-acuity procedures grew 18%, but other local factors offset the benefit. Comments were delivered at Barclays' conference and signal operational/coordination issues rather than a financial shock.

Analysis

Independent outpatient operators face a two-way headwind: changes in referral economics and rising case complexity can mechanically reduce capacity utilization even as per-case dollars tick up. A 10% increase in mean case duration typically reduces daily OR throughput by ~8–10% if block hours are unchanged; absent tighter coordination with referral sources, that throughput loss can more than offset higher acuity pricing within 2–3 quarters, producing a mid-single-digit EBITDA margin hit.

Second-order supply effects matter: implant and disposable vendors will see more volatile, higher-value orders concentrated in fewer OR-days, pressuring working capital and vendor service economics. This creates a short window (1–3 quarters) where a center with weaker scheduling discipline will face outsized cost per case and inventory inefficiencies versus hospital-employed competitors that can smooth volumes across networks.

Competitively, systems that control referral levers (employed primary care or spine/ortho hospital networks) gain negotiating leverage with commercial plans and vendors; PE-backed ASCs that can offer guaranteed commercial blocks are natural beneficiaries over the next 6–12 months. The path to restoration of stable commercial mix is operational (block reservation agreements, gainshare deals, shift-to-fixed-case-scheduling), and execution success will determine whether lost share is transient (<4 quarters) or structural (multiple years).

Contrarian angle: the market prices long-dated operational fixes as unlikely, but targeted, measurable actions (block-hour guarantees with top-20 referral groups; 90-day vendor consignment programs) can restore economics quickly. Those specific, low-capex fixes would likely show measurable utilization improvement within 2–4 quarters — if management can credibly commit to them, downside risk is more near-term than structural over the next 12 months.

Key Decisions for Investors

• Pair trade: Short SGRY vs Long HCA (1:1 notional) — 3–9 month horizon. Thesis: SGRY’s independent-referral exposure and scheduling friction make it vulnerable to further utilization compression; HCA benefits from smoothing across employed networks. Target: 20–30% downside on SGRY vs 5–10% upside on HCA; size small (2–4% portfolio) to limit idiosyncratic execution risk.
• Event-driven options: Buy SGRY 9–12 month call spread (buy ATM, sell +25% strike) after any headline-sized share-price drop — contrarian hedge with limited premium. Rationale: If management announces commercial-block guarantees or gainsharing within 2 quarters, expect a 2–3x uplift on the spread; max loss = premium (<3% allocation).
• Tactical hedge: Buy SGRY 3-month puts ahead of next quarterly earnings/payer-renewal window (small position). If utilization trends worsen or guidance is cut, puts should capture downside; if not, loss limited to premium — use this as a hedge against existing long exposure or as a low-cost speculative play.